Form 10-K ARVINAS, INC. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright
February 12, 2025 6:44 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $81.00 (from $87.00) while maintaining a Buy rating.
The analyst comments "VERITAC-2 trial design differences can impact mPFS outcome. As Arvinas plans to share the Phase 3 data from the vepdeg monotherapy trial in 1Q 2025, we remain encouraged that a CBR of 37.1% and 38.9% in 200 mg QD and 500 mg QD is impressive, and we consider it might result in a competitive mPFS in comparison to the EMERALD data of 3.8 months (elacestrant arm) versus 1.9 months (control).... More
